154634-94-3

Basic information

• Product Name: (3S,5S)-3,5-DiMethylMorpholine hydrochloride
• Synonyms: (3S,5S)-3,5-DiMethylMorpholine hydrochloride
• CAS NO: 154634-94-3
• Molecular Formula: C6H14ClNO
• Molecular Weight: 151.63446
• Mol File: 154634-94-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (3S,5S)-3,5-DiMethylMorpholine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,5S)-3,5-DiMethylMorpholine hydrochloride(154634-94-3)
• EPA Substance Registry System: (3S,5S)-3,5-DiMethylMorpholine hydrochloride(154634-94-3)

Safety Data

• Hazardous Substances Data: 154634-94-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3S,5S)-3,5-DiMethylMorpholine hydrochloride is used as a pharmaceutical intermediate for its role in the synthesis of various pharmaceuticals. Its unique structure and properties make it a valuable component in the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, (3S,5S)-3,5-DiMethylMorpholine hydrochloride serves as a key intermediate in the production of agrochemicals. Its application contributes to the development of effective pesticides, herbicides, and other agricultural chemicals that enhance crop protection and yield.
Used in Chemical Research and Development:
(3S,5S)-3,5-DiMethylMorpholine hydrochloride is utilized as a reagent in chemical research for its potential in stereoselective transformations. It aids in the development of new chemical processes and the synthesis of enantiomerically pure compounds, which are crucial in various chemical and pharmaceutical applications.
Used in the Synthesis of Chiral Compounds:
As a chiral building block, (3S,5S)-3,5-DiMethylMorpholine hydrochloride is employed in the synthesis of chiral compounds. Its specific stereochemistry allows for the creation of enantiomerically pure products, which are essential in various applications, including the production of single-enantiomer drugs with improved efficacy and reduced side effects.

Upstream product

• 256518-81-7 C₆H₁₃NO*ClH 
• 942309-59-3 meso-3,5-dimethylmorpholine-4-carboxylic acid tert-butyl ester 
• 2294-46-4 bis(2-hydroxy-1-methylethyl)amine 
• 7664-93-9 sulfuric acid 
• 154634-95-4 (3S,5S)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 
• 218595-23-4 C₆H₁₃NO*ClH 
• 942309-58-2 2-[(S)-2-hydroxy-1-methylethylamino]propan-1-ol 
• 2749-11-3 (S)-Alaninol 
• 116-09-6 hydroxy-2-propanone 
• 154596-18-6 (3S,5R)-4-tert-butoxycarbonyl-3,5-dimethylmorpholine 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

TRIAZOLYL DERIVATIVES AS SYK INHIBITORS

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1). The present invention also discloses compounds of formula I along with other pharmaceutical ac-ceptable excipients and use of the compounds to modulate the PI3K/ mTOR pathway

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS

This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R1 is aryl which may have substituent(s), R2 is aryl or indolyl, each of which may have substituent(s), R3 is hydrogen or lower alkyl, and R4 is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human beings or animals. 1

FKBP inhibitors

Compounds of formula (I), their salts and solvates, wherein the substituents are as described herein, are FKBP inhibitors.

(S,S)-3,5-dimethylmorpholine, a novel C2-symmetric auxiliary. First application in [4 + 2]-cycloadditions leading to 4-oxohexahydropyridazine derivatives

Diastereoselective Diels-Alder reactions of (S,S)-2-(3,5-dimethylmorpholino)butadienes 10 with aza-dienophiles are described, leading to cycloadducts 12 in good yields and high stereoselectivities (de = 87-96%). After double bond migration to 13, acidic a